Hemagen Diagnostics Inc
Hemagen Diagnostics, Inc., a biotechnology company, provides human and veterinary clinical diagnostic solutions worldwide. The company develops, manufactures, and markets VIRGO, a human clinical diagnostic line of immunoassays for the diagnosis of autoimmune and infectious diseases, and acute phase proteins. Its human diagnostics products also comprise Universal IFA components; supplies, controls… Read more
Market Cap & Net Worth: Hemagen Diagnostics Inc (HMGN)
Hemagen Diagnostics Inc (PINK:HMGN) has a market capitalization of $1.55K ($1.55K) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #51134 globally and #15816 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hemagen Diagnostics Inc's stock price $0.00 by its total outstanding shares 15500281 (15.50 Million).
Hemagen Diagnostics Inc Market Cap History: 2015 to 2025
Hemagen Diagnostics Inc's market capitalization history from 2015 to 2025. Data shows change from $156.55K to $1.55K (-44.96% CAGR).
Hemagen Diagnostics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hemagen Diagnostics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of HMGN by Market Capitalization
Companies near Hemagen Diagnostics Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Hemagen Diagnostics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Hemagen Diagnostics Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Hemagen Diagnostics Inc's market cap moved from $156.55K to $ 1.55K, with a yearly change of -44.96%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $1.55K | 0.00% |
| 2024 | $1.55K | 0.00% |
| 2023 | $1.55K | 0.00% |
| 2022 | $1.55K | 0.00% |
| 2021 | $1.55K | -98.59% |
| 2020 | $110.05K | +9.23% |
| 2019 | $100.75K | -18.75% |
| 2018 | $124.00K | -2.44% |
| 2017 | $127.10K | -18.00% |
| 2016 | $155.00K | -0.99% |
| 2015 | $156.55K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Hemagen Diagnostics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.55K USD |
| MoneyControl | $1.55K USD |
| MarketWatch | $1.55K USD |
| marketcap.company | $1.55K USD |
| Reuters | $1.55K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.